Enterprise Value
-68.68M
Cash
237M
Avg Qtr Burn
-20.86M
Short % of Float
5.10%
Insider Ownership
0.96%
Institutional Own.
92.99%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lunresertib (RP-6306) + gemcitabine Details Cancer, Advanced malignancies | Phase 2 Update | |
Camonsertib (RP-3500) Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
RP-1664 (PLK4 Inhibitor) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
Lunresertib (RP-6306) + FOLFIRI Details Cancer, Solid tumor/s | Phase 1 Data readout | |
Lunresertib w/ Debio 0123 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
Lunresertib (RP-6306) + gemcitabine Details Cancer, Solid tumor/s | Phase 1 Data readout | |
RP-6306 +/- Camonsertib Details Solid tumor/s, Cancer, Ovarian cancer, Endometrial cancer | Phase 1 Data readout | |
RP-3467 [Polθ ATPase inhibitor] Details Solid tumor/s, Cancer | Phase 1 Initiation |